Mar 11, 2022 · EPI Health is a growing specialty pharmaceutical company based in Charleston, South Carolina. Our goal is to deliver best-in-class medicines that address important medical needs in dermatology.

EPI Health is continually expanding our portfolio of prescription products to offer healthcare professionals and patients new and improved treatment options for dermatological conditions.

CHARLESTON, S.C.- March 11, 2022- The EP Group (privately held parent company of EPI Health, Inc.) today announced the acquisition of EPI Health, LLC (“EPI Health”) by Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN).

Everyone here understands that we all play an important role in helping EPI Health reach our goal of being a valued leader in dermatology. We are committed to providing best-in-class medications and outstanding medical services to the dermatology community and the patients they serve.

Nov 9, 2021 · NEWS PROVIDED BY EPI Health, LLC November 4, 2020 The formulary at Express Scripts and other major PBMs have expanded coverage to include Rhofade® and other EPI Health Products, bringing coverage to over 145 million US Commercial lives.

EPI Health offers innovative products to treat a variety of skin conditions. Call us with questions or to speak with a local sales representative.

To report SUSPECTED ADVERSE REACTIONS, contact EPI Health, LLC at 1-800-499-4468 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

CHARLESTON, SC, October 14, 2019 /PRNewswire/ — EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists, today announced that it has acquired RHOFADE® (oxymetazoline hydrochloride) cream, 1% (RHOFADE) and related intellectual property assets from Aclaris Therapeutics ...

CHARLESTON, USA July 6, 2021 – EPI Health announced today the publication of two posters featuring data from the head to head Phase 3 pivotal study of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) versus vehicle and Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%).

Aug 26, 2020 · W e are very excited to have the opportunity to accelerate the roll-out through a partnership with EPI Health. Under the leadership of its President, John Donofrio, EPI Health has built a culture of excellence in commercialization of dermatological drugs.